We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer.
- Authors
de Foucher, Tiphaine; Sbeih, Maria; Uzan, Jenifer; Bendifallah, Sofiane; Lefevre, Marine; Chabbert-Buffet, Nathalie; Aractingi, Selim; Uzan, Catherine; Abd Alsalam, Issam; Mitri, Rana; Fontaine, Romain H.; Daraï, Emile; Haddad, Bassam; Méhats, Céline; Ballester, Marcos; Canlorbe, Geoffroy; Touboul, Cyril
- Abstract
<bold>Background: </bold>Actual European pathological classification of early-stage endometrial cancer (EC) may show insufficient accuracy to precisely stratify recurrence risk, leading to potential over or under treatment. Micro-RNAs are post-transcriptional regulators involved in carcinogenic mechanisms, with some micro-RNA patterns of expression associated with EC characteristics and prognosis. We previously demonstrated that downregulation of micro-RNA-184 was associated with lymph node involvement in low-risk EC (LREC). The aim of this study was to evaluate whether micro-RNA signature in tumor tissues from LREC women can be correlated with the occurrence of recurrences.<bold>Methods: </bold>MicroRNA expression was assessed by chip analysis and qRT-PCR in 7 formalin-fixed paraffin-embedded (FFPE) LREC primary tumors from women whose follow up showed recurrences (R+) and in 14 FFPE LREC primary tumors from women whose follow up did not show any recurrence (R-), matched for grade and age. Various statistical analyses, including enrichment analysis and a minimum p-value approach, were performed.<bold>Results: </bold>The expression levels of micro-RNAs-184, -497-5p, and -196b-3p were significantly lower in R+ compared to R- women. Women with a micro-RNA-184 fold change < 0.083 were more likely to show recurrence (n = 6; 66%) compared to those with a micro-RNA-184 fold change > 0.083 (n = 1; 8%), p = 0.016. Women with a micro-RNA-196 fold change < 0.56 were more likely to show recurrence (n = 5; 100%) compared to those with a micro-RNA-196 fold change > 0.56 (n = 2; 13%), p = 0.001.<bold>Conclusions: </bold>These findings confirm the great interest of micro-RNA-184 as a prognostic tool to improve the management of LREC women.
- Subjects
MICRORNA; CANCER cells; CANCER chemotherapy; HEALTH outcome assessment; DISEASE progression; METASTASIS
- Publication
Journal of Translational Medicine, 2018, Vol 16, Issue 1, pN.PAG
- ISSN
1479-5876
- Publication type
journal article
- DOI
10.1186/s12967-018-1515-6